Resmed Shares Down 5.2% Premarket After U.S. FDA Approves Lilly's Weight-Loss Drug for Sleep Apnea
瑞思迈股票在盘前交易中下跌5.2%,因美国FDA批准利莱的减肥药用于睡眠呼吸暂停症。
Resmed Shares Down 5.2% Premarket After U.S. FDA Approves Lilly's Weight-Loss Drug for Sleep Apnea
瑞思迈股票在盘前交易中下跌5.2%,因美国FDA批准利莱的减肥药用于睡眠呼吸暂停症。
使用浏览器的分享功能,分享给你的好友吧